NasdaqGS - Nasdaq Real Time Price USD

Gilead Sciences, Inc. (GILD)

Time to buy GILD?

98.90

+1.02

+(1.04%)

At close: May 7 at 4:00:00 PM EDT

97.50

-1.40

(-1.42%)

Pre-Market: 9:02:35 AM EDT

Time to buy GILD?

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S. and internationally. The 52-week range of Gilead Sciences stock price was $62.07 to ...

Benzinga 10 hours ago

GILD
+1.04%
Gilead to Invest $11 Billion to Bolster Domestic Operations

Gilead Sciences said Wednesday it will invest $11 billion in U.S. research and manufacturing in the coming years, joining other drugmakers that have promised to bolster domestic capabilities as they brace for tariffs from the Trump administration. Johnson & Johnson, Merck and Novartis are among the companies that have made investment pledges for the coming years, with an aggregate total of more than $200 billion. The administration is currently conducting an investigation into potential tariffs on the pharmaceutical industry.

The Wall Street Journal 15 hours ago

GILD
+1.04%
Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally.

Investing.com 17 hours ago

GILD
+1.04%
Gilead boosts planned US investments by $11 billion amid tariff threat

The new investments, unveiled on Wednesday, will supplement an already planned spending of $21 billion to boost U.S. manufacturing and research and development through 2030, the drugmaker said. These investments will be used for new technology, building three new facilities and upgrading three existing sites, it said. Major U.S. drugmakers, including Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb, have also recently announced additional investments to boost domestic production amid the tariff threat.

Reuters 18 hours ago

GILD
+1.04%
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the company also reported Q1 financial results, announced positive outcomes for Trodelvy in cancer treatment, and shared updates on strategic partnerships, all highlighting its ongoing innovation. Despite these developments, Gilead's share price saw a minor 1.78% decline, in line with a flat market...

Simply Wall St. 19 hours ago

GILD
+1.04%
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

FOSTER CITY, Calif., May 07, 2025--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with chronic hepatitis delta virus (HDV) treated with the first-in-class entry inhibitor bulevirtide at either a 2 mg or 10 mg dose maintained virologic suppression for almost two years after stopping treatment after achieving undetectable HDV RNA at end of treatment (EOT). In participants who sustained undet

Business Wire yesterday

GILD
+1.04%
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

FOSTER CITY, Calif., May 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical response in adults with PBC regardless of prior treatment history. Another analysis provides evidence supporting that Livdelzi delivered clinically and stat

Business Wire yesterday

GILD
+1.04%
Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

NORTHAMPTON, MA / ACCESS Newswire / May 6, 2025 / At Gilead, we set and achieve bold ambitions in our fight against the world's most devastating diseases. In this installment of The Centrifuge Sessions, See Phan, Vice President, Oncology Clinical ...

ACCESS Newswire 2 days ago

GILD
+1.04%
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 days ago

GILD
+1.04%
1 Profitable Stock on Our Watchlist and 2 to Turn Down

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

StockStory 3 days ago

GILD
+1.04%

VEEV
Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

The subdued stock price reaction suggests that Gilead Sciences, Inc.'s ( NASDAQ:GILD ) strong earnings didn't offer any...

Simply Wall St. 7 days ago

GILD
+1.04%
Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the oncology business is under pressure. We advise investors to remain on the sidelines at current levels.

Zacks 7 days ago

GILD
+1.04%
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks 8 days ago

GILD
+1.04%
Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif., April 29, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:

Business Wire 8 days ago

GILD
+1.04%
Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks were rising late Tuesday afternoon, with the NYSE Health Care Index adding 1.2% a

PREMIUM
MT Newswires 8 days ago

AZN

GILD
+1.04%
Update: Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

(Updates with company statement in the fifth and sixth paragraphs.) Gilead Sciences (GILD) has ag

PREMIUM
MT Newswires 8 days ago

GILD
+1.04%
Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Gilead Sciences (NasdaqGS:GILD) recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise,...

Simply Wall St. 8 days ago

GILD
+1.04%
Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

NORTHAMPTON, MA / ACCESS Newswire / April 29, 2025 / Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch ...

ACCESS Newswire 9 days ago

GILD
+1.04%
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

FOSTER CITY, Calif., April 29, 2025--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, May 7-10, 2025, Amsterdam, furthering Gilead’s commitment to transform the lives of people living with liver disease.

Business Wire 9 days ago

GILD
+1.04%
Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks

As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor concerns.

The Wall Street Journal 11 days ago

VRTX

MRK

GILD
+1.04%

Performance Overview

Return	GILD	S&P 500 (^GSPC)
YTD	+7.82%	-4.26%
1-Year	+56.76%	+8.55%
3-Year	+81.70%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gilead Sciences, Inc. (GILD)

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead to Invest $11 Billion to Bolster Domestic Operations

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead boosts planned US investments by $11 billion amid tariff threat

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

1 Profitable Stock on Our Watchlist and 2 to Turn Down

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences to Present at Upcoming Investor Conferences

Sector Update: Health Care Stocks Gain Late Afternoon

Update: Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks

Performance Overview